Company intelligence / Profile preview
Vimelea Therapeutics
Gaithersburg, Maryland, United Statesvimelea-thera.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Vimelea is developing a novel class of small molecules inspired by the immunomodulatory protein ES‑62. These compounds selectively modulate myeloid and lymphoid immune cells implicated in cutaneous lupus erythematosus and other inflammatory diseases. The approach aims to reduce toxicity by targeting only unbalanced immune tissue. No human clinical data reported yet; all programs remain preclinical.
- Therapeutic areas
- Immunology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Exclusive worldwide license with University of Strathclyde for the core technology/platform.
Beyond the preview
Go deeper on Vimelea Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vimelea Therapeutics.